YZYongqing Zhang

Yongqing Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yongqing Zhang has a total of 57 co-authors. Here are the top co-authors by number of shared publications:

  • Chuanzhu Yan

    Department of Neurology, Shandong Key Laboratory of Mitochondrial Medicine and Rare Diseases, Research Institute of Neuromuscular and Neurodegenerative Diseases Qilu Hospital of Shandong University Jinan China

    3 shared publications
  • Chunli Li

    2 shared publications
  • Cuiping Zhao

    Department of Neurology, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, Qingdao, China

    2 shared publications
  • Dandan Zhao

    Institute of Organ Transplantation, Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China The Key Laboratory of Organ Transplantation, the Ministry of Education, the Key Laboratory of Organ Transplantation, National Health Commission, the Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences, Wuhan 430030, China

    2 shared publications
  • Jianwu Shi

    Key Lab for Special Functional Materials of Ministry of Education, Henan University, Kaifeng 475004, China

    2 shared publications
  • Sheng Zhang

    School of Chemistry and Chemical Engineering, Hainan University, 58 Renmin Avenue, Haikou 570228, Hainan

    2 shared publications

Latest Publications

  • Open Access

    Genome‐wide transcriptome differences associated with perceived discrimination in an urban, community‐dwelling middle‐aged cohort

    by Natasha L. Pacheco, Nicole Noren Hooten, Sharon F. Wu, Maame Mensah‐Bonsu, Yongqing Zhang, Kumaraswamy Naidu Chitrala, Supriyo De, Nicolle A. Mode, Ngozi Ezike, Danielle L. Beatty Moody, et al.

    Discrimination is a social adversity that is linked to several age‐related outcomes. However, the molecular drivers of these observations are poorly understood. Social adverse factors are associated with proinflammatory and interferon gene expression, but little is known about whether additional genes are associated with discrimination among both African American and White adults. In this study, we examined how perceived discrimination in African American and White adults was associated with genome‐wide transcriptome differences using RNA sequencing. Perceived discrimination was measured based on responses to self‐reported lifetime discrimination and racial discrimination. Differential gene expression and pathway analysis were conducted in a cohort ( N = 59) stratified by race, sex, and overall discrimination level. We found 28 significantly differentially expressed genes associated with race among those reporting high discrimination. Several of the upregulated genes for African American versus White adults reporting discrimination were related to immune function IGLV2‐11 , S100B , IGKV3‐20 , and IGKV4‐1 ; the most significantly downregulated genes were associated with immune modulation and cancer, LUCAT1 , THBS1 , and ARPIN . The most enriched gene ontology biological process between African American and White men reporting high discrimination was the regulation of cytokine biosynthetic processes. The immune response biological process was significantly lower for African American women compared to White women reporting high discrimination. Discrimination was associated with the expression of small nucleolar RNAs, long noncoding RNAs, and microRNAs associated with energy homeostasis, cancer, and actin. Understanding the pathways through which adverse social factors like discrimination are associated with gene expression is crucial in advancing knowledge of age‐related health disparities.


  • Open Access

    Amygdala abnormalities across disease stages in patients with sporadic amyotrophic lateral sclerosis

    by Shuangwu Liu, Yuying Zhao, Qingguo Ren, Dong Zhang, Kai Shao, Pengfei Lin, Ying Yuan, Tingjun Dai, Yongqing Zhang, Ling Li, et al.

    To examine selective atrophy patterns and resting‐state functional connectivity (FC) alterations in the amygdala at different stages of amyotrophic lateral sclerosis (ALS), and to explore any correlations between amygdala abnormalities and neuropsychiatric symptoms. We used the King's clinical staging system for ALS to divide 83 consecutive patients with ALS into comparable subgroups at different disease stages. We explored the pattern of selective amygdala subnucleus atrophy and amygdala‐based whole‐brain FC alteration in these patients and 94 healthy controls (HCs). Cognitive and emotional functions were also evaluated using a neuropsychological test battery. There were no significant differences between ALS patients at King's stage 1 and HCs for any amygdala subnucleus volumes. Compared with HCs, ALS patients at King's stage 2 had significantly lower left accessory basal nucleus and cortico‐amygdaloid transition volumes. Furthermore, ALS patients at King's stage 3 demonstrated significant reductions in most amygdala subnucleus volumes and global amygdala volumes compared with HCs. Notably, amygdala‐cuneus FC was increased in ALS patients at King's stage 3. Specific subnucleus volumes were significantly associated with Mini‐Mental State Examination scores and Hamilton Anxiety Rating Scale scores in ALS patients. In conclusions, our study provides a comprehensive profile of amygdala abnormalities in ALS patients. The pattern of amygdala abnormalities in ALS patients differed greatly across King's clinical disease stages, and amygdala abnormalities are an important feature of patients with ALS at relatively advanced stages. Moreover, our findings suggest that amygdala volume may play an important role in anxiety and cognitive dysfunction in ALS patients.


  • Open Access

    Clinicopathologic Profiles of Sporadic Late-Onset Nemaline Myopathy

    by Bing Zhao, Tingjun Dai, Dandan Zhao, Xiaotian Ma, Cuiping Zhao, Ling Li, Yuan Sun, Yongqing Zhang, Yaping Yan, Jian-Qiang Lu, et al.

    Background and Objectives Sporadic late-onset nemaline myopathy (SLONM) is a treatable or otherwise fatal myopathy. Diagnosis of SLONM is still challenging, and no therapeutic consensus has been achieved. Here, we reported the clinicopathologic features and long-term follow-up data of SLONM in a Chinese cohort. Methods We performed a retrospective evaluation of clinical, pathologic, and treatment outcomes of 17 patients with SLONM diagnosed between March 1986 and April 2021 at our neuromuscular center. Immunohistochemistry (IHC) with antibodies against 5 Z-disc–associated proteins was performed in the muscle biopsies of SLONM to identify a potential pathologic marker in aid of diagnosis. In comparison, we also performed muscle IHC in patients with selective type II fiber atrophy (n = 22), neurogenic atrophy (n = 22), mitochondrial myopathy (n = 5), immune-mediated necrotizing myopathy (n = 5), and normal controls (n = 5). Results Most of the patients exhibited asymmetric limb muscles weakness (71%, 12/17) and neck extensor weakness (53%, 9/17). Immunofixation electrophoresis was performed in 11 patients, and 4 of them were identified with monoclonal gammopathy of undetermined significance (MGUS). EMG from 16 patients demonstrated a myopathic pattern with spontaneous activities in 69% (11/16) of them. Muscle MRI showed preferential involvement of paraspinal, gluteus minimus and medius, semimembranosus, and soleus muscles. Suspected nemaline bodies on modified Gomori trichrome were confirmed by IHC using anti–α-actinin antibody (100%, 17/17), anti-myotilin antibody (94%, 16/17), anti-desmin antibody (94%, 16/17), anti–α-B crystallin antibody (65%, 11/17), and anti-telethonin antibody (18%, 3/17) with various positive rates. Notably, anti–α-actinin IHC showed the highest percentage of strongly positive staining (77%, 13/17), being the only one without negative results. Moderate improvement following autologous stem cell transplantation (ASCT) was noted in 3/4 patients with MGUS; favorable outcomes were also achieved in 6/7 patients without MGUS, including 3 patients with complete recovery who were given a combined treatment of prednisone and another immunosuppressant. Discussion SLONM is a treatable myopathy with ASCT or traditional immunotherapy, especially when combined with steroids and immunosuppressants. Anti–α-actinin immunostaining is the most reliable pathologic marker to identify rod-bearing fibers, and it should be performed routinely in adult patients with undiagnosed nonnecrotic myopathies.


  • Open Access

    Cerebrotendinous xanthomatosis with peripheral neuropathy: a clinical and neurophysiological study in Chinese population

    by Shu Zhang, Wei Li, Rui Zheng, Bing Zhao, Yongqing Zhang, Dandan Zhao, Cuiping Zhao, Chuanzhu Yan, Yuying Zhao

    Background: Cerebrotendinous xanthomatosis (CTX) is an inborn disorder of bile acid metabolism caused by deficiency of sterol 27-hydroxylase (CYP27A1) gene. CTX-related peripheral neuropathy has rarely been discussed in Chinese population. Here, we reported 6 CTX cases and performed a literature review focused on CTX with neuropathy to summarize its clinical and neurophysiological features. Methods: All clinical data of 6 CTX cases were collected, and 21 reported Chinese CTX patients (including this study) were reviewed and summarized. Results: Clinical manifestations of 6 CTX cases showed great heterogeneity. Cognitive decline, spastic paraplegia, cerebellar ataxia and advanced bulbar palsy were common neurological disorders, often accompanied by non-neurological signs like xanthomas, cataract, diarrhea and pes cavus. Dentate nuclei hyperintensity with or without hyposignal is a valuable MRI hallmark. Pooling our patients and literature review together, peripheral neuropathy was predominant sensorimotor demyelinating type in Chinese population, with an evident length dependent pattern and increased vulnerability in motor nerves. Demyelinating and axonal degeneration tend to exist in severe neuropathy. Three novel mutations including c.1055C>A; c.432T>G; c.472T>G were identified in CYP27A1 and predicted to be pathogenic. Oral CDCA therapy could ameliorate some of the existing symptoms and provide clinical stability, but it could not cease disease progression completely. Conclusions: Our study broadens the phenotype and mutation spectrum of CTX. Patients with cognitive decline, spastic tetraparesis, cerebellar ataxia and bulbar palsy, should be highly suspicious of CTX even no xanthomas disclosed. Peripheral neuropathy was predominant sensorimotor demyelinating type in Chinese population, with mixed axonal and demyelinating type in severe cases. Three novel likely pathogenic mutations including c.1055C>A; c.432T>G; c.472T>G were identified in CYP27A1.


  • Open Access

    Studies on Chemical Constituents of Twigs of Trichosanthes kirilowii Maxim

    by Wenjuan Duan, Shaobin Pan, Zongyuan Yu, Xiao Wang, Jia Li, Yongqing Zhang


  • Open Access

    CCDC 1013179: Experimental Crystal Structure Determination

    by Chunli Li, Yongqing Zhang, Sheng Zhang, Jianwu Shi, Yu‐He Kan, Hua Wang

  • Open Access

    CCDC 1013177: Experimental Crystal Structure Determination

    by Chunli Li, Yongqing Zhang, Sheng Zhang, Jianwu Shi, Yu‐He Kan, Hua Wang